Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

This study is ongoing, but not recruiting participants.
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Synta Pharmaceuticals Corp.
Information provided by (Responsible Party):
Jeffrey W. Clark, MD, Massachusetts General Hospital Identifier:
First received: January 13, 2010
Last updated: April 6, 2017
Last verified: April 2017
In this research study, the investigators are looking to see how effective STA-9090 is in treating esophagogastric cancer. The investigators will also evaluate the side effects of STA-9090, and examine the relationship between the presence of HSP-90 and how well study participants respond to STA-9090. STA-9090 works by blocking a protein in tumor cells called HSP90, which is thought to play a role in tumor growth. By interfering with this protein's function, STA-9090 may help kill tumor cells. This drug has been used in other research studies and information from those other research studies suggests that this agent may help to slow tumor growth in esophagogastric cancer.

Condition Intervention Phase
Esophagogastric Cancer
Drug: STA-9090
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • To evaluate the efficacy of STA-9090 in patients who have progressed through prior 1st-line treatment for esophagogastric cancer, as measured by overall response rate. [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • To determine progression-free survival. [ Time Frame: 3 years ]
  • To retrospectively determine the prevalence of HSP-90 clients in the tumors of subjects treated on trial. [ Time Frame: 2 years ]
  • To correlate the presence of HSP-clients with response rate and progression-free survival [ Time Frame: 3 years ]
  • To determine safety, tolerability and adverse event profiles of this therapeutic regimen in the treatment of esophagogastric cancer. [ Time Frame: 2 years ]

Enrollment: 20
Study Start Date: August 2010
Estimated Study Completion Date: April 2018
Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: STA-9090
All subjects receive STA-9090
Drug: STA-9090
Given intravenously on Day 1, 8 and 15 of each 4 week cycle.

Detailed Description:
  • Each treatment cycle lasts 4 weeks during which time the study drug will be administered for three consecutive weeks followed by 1 week of no study drug. STA-9090 will be given by intravenous infusion.
  • Participants will come to the clinic on Days 1, 8, and 15 of all cycles. At these visits, the following tests and procedures will be performed: Review of current medications and any side effects experienced; Performance status evaluation; Physical examination; Vital signs; Routine blood tests; CT scan of the chest, abdomen, and pelvis (every 2 cycles) and Optional FDG-PET scan (every 2 cycles).
  • Participants may remain on this research study for as long as their cancer is responding to the study drug and they are not experiencing any severe side effects.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants must have histologically or cytologically confirmed advanced esophageal, gastroesophageal, or gastric cancer. When possible, archived biopsy or resection specimens must be available for correlative SNaPshot and FISH studies.
  • Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as 20mm or greater with conventional techniques or as 10mm or greater with spiral CT scan (per RECIST criteria).
  • Participants must have progressed through prior 1st-line therapy. For the purposes of this trial, neoadjuvant chemoradiation or peri-operative chemotherapy may be considered as prior 1st-line treatment in the event of metastatic recurrence.
  • 18 years of age or older
  • Life expectancy of greater than 12 weeks
  • ECOG Performance status of 1 or greater
  • Participants must have normal organ and marrow function as defined in the protocol.
  • Participants must have adequate peripheral IV access. Administration of STA-9090 via indwelling catheters is prohibited at this time.
  • No concurrent active primary or metastatic cancer other than superficial squamous cell or basal cell skin cancer.
  • At least 3 weeks or 5 half-lives must have elapsed between the most recent dose of any prior anticancer therapy and the start date of treatment with STA-9090. Participants must have resolution to baseline of all toxicities associated with prior anticancer therapies.
  • Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.

Exclusion Criteria:

  • Participants may not be receiving any other standard or investigational anticancer agents, with the exception of hormonal therapy.
  • Participants with known CNS metastases must have received whole-brain radiation or other appropriate therapy not less than 4 weeks prior to starting the study drug and exhibit clinical stability of brain disease.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to STA-9090 or to the excipients PEG 300 and Polysorbate 80.
  • Ventricular ejection fraction of 55% or less at baseline.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia other than chronic atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study. Breastfeeding should be discontinued
  • HIV-positive individuals on combination antiretroviral therapy are ineligible.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01167114

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Synta Pharmaceuticals Corp.
Principal Investigator: Jeffrey W Clark, MD Massachusetts General Hospital
  More Information

Responsible Party: Jeffrey W. Clark, MD, Principal Investigator, Massachusetts General Hospital Identifier: NCT01167114     History of Changes
Other Study ID Numbers: 09-422
Study First Received: January 13, 2010
Last Updated: April 6, 2017

Keywords provided by Massachusetts General Hospital:
STA-9090 processed this record on April 28, 2017